| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
AACR Annual Meeting 2021
|
Reeves, Cheryl
|
|
|
22 |
5 |
p. e185
|
artikel
|
| 2 |
Adjuvant pembrolizumab for melanoma: update from the EORTC 1325-MG/KEYNOTE-054 trial
|
Indini, Alice
|
|
|
22 |
5 |
p. 573-575
|
artikel
|
| 3 |
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial
|
Eggermont, Alexander M M
|
|
|
22 |
5 |
p. 643-654
|
artikel
|
| 4 |
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial
|
Bottomley, Andrew
|
|
|
22 |
5 |
p. 655-664
|
artikel
|
| 5 |
Are immune checkpoint combination therapies for intermediate and poor risk renal cell carcinoma better than immune checkpoint inhibitors combined with kinase inhibitors?
|
McDermott, David F
|
|
|
22 |
5 |
p. 593-594
|
artikel
|
| 6 |
Are we already in the era of total neoadjuvant treatment for rectal cancer?
|
Socha, Joanna
|
|
|
22 |
5 |
p. 575-577
|
artikel
|
| 7 |
Carcinogenicity of gentian violet, leucogentian violet, malachite green, leucomalachite green, and CI Direct Blue 218
|
|
|
|
22 |
5 |
p. 585-586
|
artikel
|
| 8 |
Cervical cancer screening and New Zealand's uncomfortable truths
|
The Lancet Oncology,
|
|
|
22 |
5 |
p. 571
|
artikel
|
| 9 |
Chemotherapy and radiotherapy in locally advanced head and neck cancer: an individual patient data network meta-analysis
|
Petit, Claire
|
|
|
22 |
5 |
p. 727-736
|
artikel
|
| 10 |
China's oncology drug market on the rise
|
McCall, Chris
|
|
|
22 |
5 |
p. 586-587
|
artikel
|
| 11 |
Concerns over the World Cancer Declaration outcome analysis
|
Sarode, Sachin C
|
|
|
22 |
5 |
p. e183
|
artikel
|
| 12 |
Conquer cancer for everyone
|
Caraceni, Augusto
|
|
|
22 |
5 |
p. 583-584
|
artikel
|
| 13 |
Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial
|
Matasar, Matthew J
|
|
|
22 |
5 |
p. 678-689
|
artikel
|
| 14 |
Correction to Lancet Oncol 2021; 22: 512–24
|
|
|
|
22 |
5 |
p. e184
|
artikel
|
| 15 |
Correction to Lancet Oncol 2021; 22: 489–98
|
|
|
|
22 |
5 |
p. e184
|
artikel
|
| 16 |
Correction to Lancet Oncol 2021; 22: 166–67
|
|
|
|
22 |
5 |
p. e184
|
artikel
|
| 17 |
Diffuse intrinsic pontine glioma: a clinic in Mexico, social media, and unpublishable data
|
Bouche, Gauthier
|
|
|
22 |
5 |
p. 595-596
|
artikel
|
| 18 |
Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study
|
Coleman, Robert L
|
|
|
22 |
5 |
p. 609-619
|
artikel
|
| 19 |
Extent of French nuclear tests in Polynesia revealed
|
Das, Manjulika
|
|
|
22 |
5 |
p. 587-588
|
artikel
|
| 20 |
GDPR obstructs cancer research data sharing
|
Gourd, Elizabeth
|
|
|
22 |
5 |
p. 592
|
artikel
|
| 21 |
Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial
|
Andre, Thierry
|
|
|
22 |
5 |
p. 665-677
|
artikel
|
| 22 |
Increasing the value of radiotherapy in breast cancer
|
Buchholz, Thomas A
|
|
|
22 |
5 |
p. 572-573
|
artikel
|
| 23 |
Induction chemotherapy with lobaplatin and fluorouracil versus cisplatin and fluorouracil followed by chemoradiotherapy in patients with stage III–IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised, controlled, phase 3 trial
|
Lv, Xing
|
|
|
22 |
5 |
p. 716-726
|
artikel
|
| 24 |
Intraoperative irradiation for early breast cancer (ELIOT): long-term recurrence and survival outcomes from a single-centre, randomised, phase 3 equivalence trial
|
Orecchia, Roberto
|
|
|
22 |
5 |
p. 597-608
|
artikel
|
| 25 |
Limitations of the PRODIGE 7 trial
|
Rovers, Koen P
|
|
|
22 |
5 |
p. e174
|
artikel
|
| 26 |
Limitations of the PRODIGE 7 trial
|
Cashin, Peter
|
|
|
22 |
5 |
p. e177
|
artikel
|
| 27 |
Limitations of the PRODIGE 7 trial
|
Ströhlein, Michael A
|
|
|
22 |
5 |
p. e178
|
artikel
|
| 28 |
Limitations of the PRODIGE 7 trial
|
Bhatt, Aditi
|
|
|
22 |
5 |
p. e175
|
artikel
|
| 29 |
Limitations of the PRODIGE 7 trial
|
Carboni, Fabio
|
|
|
22 |
5 |
p. e176
|
artikel
|
| 30 |
Limitations of the PRODIGE 7 trial – Authors' reply
|
Quénet, François
|
|
|
22 |
5 |
p. e179-e180
|
artikel
|
| 31 |
99mTc-HDP bone scintigraphy confirming parathyroid hormone-related peptide paraneoplastic syndrome in metastatic breast cancer
|
Braat, Arthur J A T
|
|
|
22 |
5 |
p. e216
|
artikel
|
| 32 |
Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial
|
Conroy, Thierry
|
|
|
22 |
5 |
p. 702-715
|
artikel
|
| 33 |
New Canadian law on medical assisted dying
|
Das, Manjulika
|
|
|
22 |
5 |
p. 588-589
|
artikel
|
| 34 |
New technical guidance to boost global radiotherapy access
|
Wilkinson, Emma
|
|
|
22 |
5 |
p. 589-590
|
artikel
|
| 35 |
Next generation platinum salt in nasopharygeal carcinoma
|
Cavalieri, Stefano
|
|
|
22 |
5 |
p. 577-578
|
artikel
|
| 36 |
Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial
|
Poveda, Andrés
|
|
|
22 |
5 |
p. 620-631
|
artikel
|
| 37 |
Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3 trial
|
Friedlander, Michael
|
|
|
22 |
5 |
p. 632-642
|
artikel
|
| 38 |
PET-guided omission of radiotherapy in Hodgkin lymphoma
|
Shibusawa, Motoharu
|
|
|
22 |
5 |
p. e181
|
artikel
|
| 39 |
PET-guided omission of radiotherapy in Hodgkin lymphoma – Authors' reply
|
Borchmann, Peter
|
|
|
22 |
5 |
p. e182
|
artikel
|
| 40 |
Placenta can provide new insights on the genetics of cancer
|
Burki, Talha Khan
|
|
|
22 |
5 |
p. 591
|
artikel
|
| 41 |
Public reporting of outcomes in radiation oncology: the National Prostate Cancer Audit
|
Aggarwal, Ajay
|
|
|
22 |
5 |
p. e207-e215
|
artikel
|
| 42 |
Real-time fluorescence imaging in intraoperative decision making for cancer surgery
|
Lauwerends, Lorraine J
|
|
|
22 |
5 |
p. e186-e195
|
artikel
|
| 43 |
Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial
|
Lamarca, Angela
|
|
|
22 |
5 |
p. 690-701
|
artikel
|
| 44 |
Short-term safety of the BNT162b2 mRNA COVID-19 vaccine in patients with cancer treated with immune checkpoint inhibitors
|
Waissengrin, Barliz
|
|
|
22 |
5 |
p. 581-583
|
artikel
|
| 45 |
Surveillance for subsequent neoplasms of the CNS for childhood, adolescent, and young adult cancer survivors: a systematic review and recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group
|
Bowers, Daniel C
|
|
|
22 |
5 |
p. e196-e206
|
artikel
|
| 46 |
The Global Breast Cancer Initiative: a strategic collaboration to strengthen health care for non-communicable diseases
|
Anderson, Benjamin O
|
|
|
22 |
5 |
p. 578-581
|
artikel
|
Tijdschrift beschrijving